SS Innovations International Inc. has successfully performed the first-ever robotic cardiac surgery in Indonesia, a milestone the company claims highlights the transformative potential of its surgical robotic system (SSi Mantra).

The procedures, a bilateral IMA CABG (coronary artery bypass graft), and ASD repair and beating heart totally endoscopic coronary artery bypass (TECAB), were conducted at the Harapan Kita National Cardiac Hospital in Jakarta, India. This marks a significant milestone for both the hospital and Indonesia’s healthcare sector, highlighting the advancements made possible through the use of SSi Mantra.

Instrumental in achieving this milestone is SS Innovations Founder/Chairman/CEO Dr. Sudhir Srivastava, who performed the first beating heart TECAB in Indonesia, accompanied by his team from the company and Harapan Kita support staff led by Dr. Dudy Hanafy. This achievement highlights the capabilities of the SSi Mantra Surgical Robotic System and reflects Dr. Srivastava’s expertise.

“We are proud to partner with Harapan Kita National Cardiac Hospital to bring the most technologically advanced and cost-effective solutions to cardiac surgery to Indonesia. Reaching this milestone with SSi Mantra is a testament to our vision of transforming surgical practices, enhancing access, and driving the global adoption of cost-effective robotic surgery,” Dr. Srivastava said. “This collaboration addresses the critical need for safe, timely, and affordable cardiac care while offering patients less invasive options and an improved quality of life. The successful use of SSi Mantra in cardiac surgeries positions the company to accelerate momentum, gain market share in key markets, and continue our mission of making affordable robotic surgery accessible to patients worldwide.”

The company believes the launch of the robotic cardiac surgery program at Harapan Kita represents the beginning of a new era in cardiac care in Indonesia. After the initial TECAB procedure, SS Innovations—in collaboration with Harapan Kita’s surgical team—performed seven to eight additional robotic-assisted procedures over the next several days, including LIMA, BIMA, TECAB, and ASD repair procedures.

“We have been exploring the integration of robotic surgery in cardiovascular care at the Harapan Kita hospital and reviewed the globally available surgical robotic systems,” stated Dr. Iwan Dakota, director and interventional cardiologist at NCVC Harapan Kita. “We found the SSi Mantra is the only system supporting the full spectrum of robotic cardiac surgery, including totally endoscopic coronary artery bypass. Given its unique capabilities, we invited Dr. Srivastava’s team to demonstrate how the SSi Mantra performs as compared to other systems. The potential for implementing robotic surgery in our country is highly promising.”

The SSi Mantra Surgical Robotic System is a modular multi-arm system with many advanced technology features. It allows for the use of three to five robotic arms, has an open-faced ergonomic Surgeon Command Centre, 32-inch large 3D 4K monitor, a 23-inch 2D Touch panel monitor for all patient related information display, a virtual real-time image of the robotic Patient Side Arm Carts, and the ability to superimpose 3D models of diagnostic imaging. The Vision Cart gives the table-side team the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The modular robotic arms give flexibility in positioning and the number of arms to be used. This allows for collision-free conduct of surgical operations. There are more than 40 different types of robotic endo-surgical instruments that can be used for different specialties, including cardiac surgery. The learning curve for surgeons is shorter due to the SSi Mantra’s ergonomic design and user-friendly features. 

The SSi Mantra has been clinically validated in India in more than 80 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and the European Union and anticipates receiving U.S. Food and Drug Administration approval to market and CE Mark approval in the second half of 2025.

SS Innovations International Inc. develops surgical robotic technologies with the aim to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra” its range of surgical instruments capable of supporting various surgical procedures including robotic cardiac surgery. SS Innovations’ business operations are headquartered in India and the company plans to expand the presence of its surgical robotic solutions globally.